argenx SE (ARGX)
Data as of September 4, 2026 · Biotechnology
Stockbruh grade: Strong 5/5 metrics rated Sunny
What does argenx SE do?
🔬🌍 argenx SE, a biotech powerhouse based in Breda, NL, is creating game-changing therapies for autoimmune diseases worldwide. With a diverse pipeline of innovative treatments, including efgartigimod and cusatuzumab, they're working to tackle conditions like myasthenia gravis and cancer. With strategic partnerships and collaborations, argenx SE is on a mission to revolutionize healthcare. 💪🔬.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ☀️ Strong | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $1053.46 | Market Cap | — |
| Exchange | NASDAQ Global Select | | |
Plain-English Analysis
What's it worth?
Based on 5-year performance trends, argenx SE has historically delivered strong returns. Sign up free for full valuation analysis including P/E, DCF estimates, and Stockbruh's plain-English take on whether this stock looks cheap or expensive right now.
How the business works
🔬🌍 argenx SE, a biotech powerhouse based in Breda, NL, is creating game-changing therapies for autoimmune diseases worldwide. With a diverse pipeline of innovative treatments, including efgartigimod and cusatuzumab, they're working to tackle conditions like myasthenia gravis and cancer. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — argenx SE appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.